

DAFTAR PUSTAKA

- Abudabous, A. *et al.* (2021) 'KRAS mutations in patients with colorectal cancer in Libya', *Molecular and Clinical Oncology*, 15(4), pp. 11–16. Available at: <https://doi.org/10.3892/mco.2021.2359>.
- Ahadova, A. *et al.* (2018) 'Three molecular pathways model colorectal carcinogenesis in Lynch syndrome', *International Journal of Cancer*, 143(1), pp. 139–150. Available at: <https://doi.org/10.1002/ijc.31300>.
- Akiyoshi, T., Kobunai, T. and Watanabe, T. (2012) 'Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer', *Surgery Today*, 42(8), pp. 713–719. Available at: <https://doi.org/10.1007/s00595-012-0223-8>.
- Andrade, F. *et al.* (2023) 'The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers', *Pharmaceutics*. Multidisciplinary Digital Publishing Institute (MDPI). Available at: <https://doi.org/10.3390/pharmaceutics15061686>.
- Asako, K. *et al.* (2023) 'Prognostic Value of KRAS Exon-specific Mutations in Patients With Colorectal Cancer', *Anticancer Research*, 43(4), pp. 1563–1568. Available at: <https://doi.org/10.21873/anticancer.16306>.
- Augestad, K.M., Merok, M.A. and Ignatovic, D. (2017) 'Tailored treatment of colorectal cancer: Surgical, molecular, and genetic considerations', *Clinical Medicine Insights: Oncology*, 11. Available at: <https://doi.org/10.1177/1179554917690766>.
- Budinska, E. *et al.* (2013) 'Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer', *The Journal of Pathology*, 231(1), pp. 63–76. Available at: <https://doi.org/10.1002/path.4212>.
- Bupathi, M. and Wu, C. (2016) 'Biomarkers for immune therapy in colorectal cancer: Mismatchrepair deficiency and others', *Journal of Gastrointestinal Oncology*, 7(5), pp. 713–720. Available at: <https://doi.org/10.21037/jgo.2016.07.03>.

- Cefali, M. *et al.* (2021) 'Research progress on KRAS mutations in colorectal cancer', *Journal of Cancer Metastasis and Treatment*, 7. Available at: <https://doi.org/10.20517/2394-4722.2021.61>.
- Cekani, E. *et al.* (2022) 'Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers', *Cancers*. MDPI. Available at: <https://doi.org/10.3390/cancers14174103>.
- Cionca, F.L. *et al.* (2018) 'Mutational status of KRAS and MMR genes in a series of colorectal carcinoma cases', *Romanian Journal of Morphology and Embryology*, 59(1), pp. 121–129.
- Cubiellaa, J. *et al.* (2018) 'Clinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 Update', *Gastroenterología y Hepatología*, 4(9), pp. 585–596.
- Dohrn, N. and Klein, M.F. (2023) 'Colorectal cancer: current management and future perspectives', *British Journal of Surgery*, 110(10), pp. 1256–1259. Available at: <https://doi.org/10.1093/bjs/znad095>.
- Dong, Y. *et al.* (2018a) 'Tumor Suppressor Functions of miR-133a in Colorectal Cancer', *Molecular Cancer Research*, 11(9), pp. 1051–1060. Available at: <https://doi.org/10.1158/1541-7786.MCR-13-0061>.
- Dong, Y. *et al.* (2013b) 'Tumor Suppressor Functions of miR-133a in Colorectal Cancer', *Molecular Cancer Research*, 11(9), pp. 1051–1060. Available at: <https://doi.org/10.1158/1541-7786.MCR-13-0061>.
- Duan, B. *et al.* (2022) 'Colorectal Cancer: An Overview', in *Gastrointestinal Cancer*. Exon Publications.
- Effendi-YS, R. and Rey, I. (2019) 'Molecular Diagnostics in Colorectal Cancer', *Molecular Diagnostics in Cancer Patients*, pp. 143–155. Available at: https://doi.org/10.1007/978-981-13-5877-7_9.
- Erbs, E. *et al.* (2020) 'The impact of mismatch repair status to the preoperative staging of colon cancer: implications for clinical management', *Colorectal Cancer*, 9(2). Available at: <https://doi.org/10.2217/crc-2020-0001>.

- Gong, Q. *et al.* (2018) 'Mismatch repair-deficient status associates with favorable prognosis of eastern Chinese population with sporadic colorectal cancer', *Oncology Letters*, 15(5), pp. 7007–7013. Available at: <https://doi.org/10.3892/ol.2018.8192>.
- Van Grieken, N.C.T. *et al.* (2013) 'KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study', *British Journal of Cancer*, 108(7), pp. 1495–1501. Available at: <https://doi.org/10.1038/bjc.2013.109>.
- Gyparaki, M.-T., Basdra, E.K. and Papavassiliou, A.G. (2018) 'DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer', *Journal of Molecular Medicine*, 91(11), pp. 1249–1256. Available at: <https://doi.org/10.1007/s00109-013-1088-z>.
- Hagland, H.R. *et al.* (2013) 'Molecular Pathways and Cellular Metabolism in Colorectal Cancer', *Digestive Surgery*, 30(1), pp. 12–25. Available at: <https://doi.org/10.1159/000347166>.
- He, E.Y. *et al.* (2016) 'The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study', *The Oncologist*, 21(5), pp. 618–625. Available at: <https://doi.org/10.1634/theoncologist.2015-0530>.
- Hu, J. *et al.* (2022) 'Predicting Kirsten Rat Sarcoma Virus Gene Mutation Status in Patients With Colorectal Cancer by Radiomics Models Based on Multiphasic CT', *Frontiers in Oncology*, 12. Available at: <https://doi.org/10.3389/fonc.2022.848798>.
- Huang, L. *et al.* (2021) 'KRAS mutation: from undruggable to druggable in cancer', *Signal Transduction and Targeted Therapy*, 6(1), p. 386. Available at: <https://doi.org/10.1038/s41392-021-00780-4>.
- Hull, R. *et al.* (2020) 'Colorectal cancer genetics, incidence and risk factors: In search for targeted therapies', *Cancer Management and Research*, 12, pp. 9869–9882. Available at: <https://doi.org/10.2147/CMAR.S251223>.

- Jass, J.R. (2007) 'Classification of colorectal cancer based on correlation of clinical, morphological and molecular features', *Histopathology*, 50(1), pp. 113–130. Available at: <https://doi.org/10.1111/j.1365-2559.2006.02549.x>.
- Jinesh, G.G. *et al.* (2018) 'Molecular genetics and cellular events of K-Ras-driven tumorigenesis', *Oncogene*. Nature Publishing Group, pp. 839–846. Available at: <https://doi.org/10.1038/onc.2017.377>.
- Kalady, M.F. *et al.* (2010) 'Gene Signature Is Associated with Early Stage Rectal Cancer Recurrence', *Journal of the American College of Surgeons*, 211(2), pp. 187–195. Available at: <https://doi.org/10.1016/j.jamcollsurg.2010.03.035>.
- Karaayvaz, M., Zhai, H. and Ju, J. (2018) 'miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer', *Cell Death & Disease*, 4(6), pp. e659–e659. Available at: <https://doi.org/10.1038/cddis.2013.193>.
- Kasi, A. *et al.* (2020) 'Molecular Pathogenesis and Classification of Colorectal Carcinoma', *Current Colorectal Cancer Reports*, 16(5), pp. 97–106. Available at: <https://doi.org/10.1007/s11888-020-00458-z>.
- Kelley, M.P. *et al.* (2019) *Operative Anatomy of the Colon, Rectum, and Anus*. Eighth Edi, *Shackelford's Surgery of the Alimentary Tract: 2 Volume Set*. Eighth Edi. Elsevier Inc. Available at: <https://doi.org/10.1016/B978-0-323-40232-3.00143-6>.
- Kementerian Kesehatan (2020) *Pencegahan Kanker*. Available at: <https://promkes.kemkes.go.id/>.
- Kim, J.W. *et al.* (2018) 'Molecular Markers Predict Distant Metastases After Adjuvant Chemoradiation for Rectal Cancer', *International Journal of Radiation OncologyBiologyPhysics*, 84(5), pp. e577–e584. Available at: <https://doi.org/10.1016/j.ijrobp.2012.07.2371>.
- Kim, T.W. *et al.* (2023) 'The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The

- KASID Multicenter Study', *Oncology (Switzerland)*, 101(1), pp. 49–58. Available at: <https://doi.org/10.1159/000527285>.
- Krogh, K. and Laurberg, S. (2017) 'Physiology of Colon, Rectum, and Anus', in *Coloproctology*. Springer Berlin Heidelberg, pp. 23–35. Available at: https://doi.org/10.1007/978-3-662-53210-2_3.
- Lee, J.K. and Chan, A.T. (2018) 'Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status', *Current Colorectal Cancer Reports*, 7(2), pp. 136–144. Available at: <https://doi.org/10.1007/s11888-011-0091-4>.
- Lewandowska, A. *et al.* (2022) 'Title: Risk Factors for the Diagnosis of Colorectal Cancer', *Cancer Control*, 29, pp. 1–15. Available at: <https://doi.org/10.1177/10732748211056692>.
- Li, H.-Y. *et al.* (2013) 'MicroRNA-451 Inhibits Growth of Human Colorectal Carcinoma Cells via Downregulation of Pi3k/Akt Pathway', *Asian Pacific Journal of Cancer Prevention*, 14(6), pp. 3631–3634. Available at: <https://doi.org/10.7314/APJCP.2013.14.6.3631>.
- Li, J.X. *et al.* (2022) 'Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives', *Frontiers in Pharmacology*. Frontiers Media S.A. Available at: <https://doi.org/10.3389/fphar.2022.875330>.
- Li, W. *et al.* (2015) 'Distinct clinicopathological patterns of mismatch repair status in colorectal cancer stratified by KRAS mutations', *PLoS ONE*, 10(6), pp. 1–12. Available at: <https://doi.org/10.1371/journal.pone.0128202>.
- Lian, S.Y. *et al.* (2023) 'KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China', *Medicine (United States)*, 102(9), p. E33115. Available at: <https://doi.org/10.1097/MD.00000000000033115>.
- Liao, W.-T. *et al.* (2013) 'microRNA-224 Promotes Cell Proliferation and Tumor Growth in Human Colorectal Cancer by Repressing *PHLPP1* and *PHLPP2*',

Clinical Cancer Research, 19(17), pp. 4662–4672. Available at: <https://doi.org/10.1158/1078-0432.CCR-13-0244>.

Lou, X. *et al.* (2013) 'Decreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer', *Journal of Surgical Oncology*, 108(4), pp. 230–235. Available at: <https://doi.org/10.1002/jso.23380>.

Mármol, I. *et al.* (2017) 'Colorectal carcinoma: A general overview and future perspectives in colorectal cancer', *International Journal of Molecular Sciences*, 18(1). Available at: <https://doi.org/10.3390/ijms18010197>.

Mattiuzzi, C., Sanchis-Gomar, F. and Lippi, G. (2019) 'Concise update on colorectal cancer epidemiology', *Annals of Translational Medicine*, 7(21), pp. 609–609. Available at: <https://doi.org/10.21037/atm.2019.07.91>.

Meng, M. *et al.* (2021) 'The current understanding on the impact of KRAS on colorectal cancer', *Biomedicine and Pharmacotherapy*, 140(May), p. 111717. Available at: <https://doi.org/10.1016/j.biopha.2021.111717>.

Mlcochova, J. *et al.* (2013) 'MicroRNAs targeting EGFR signalling pathway in colorectal cancer', *Journal of Cancer Research and Clinical Oncology*, 139(10), pp. 1615–1624. Available at: <https://doi.org/10.1007/s00432-013-1470-9>.

Mulholland, M.W. *et al.* (2017) *Greenfield's Surgery: Scientific Principles & Practic. Six.*

Ni Nyoman, A.D. *et al.* (2022a) 'The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali', *Indonesian Journal of Biotechnology*, 27(1), pp. 29–35. Available at: <https://doi.org/10.22146/ijbiotech.67506>.

Ni Nyoman, A.D. *et al.* (2022b) 'The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali', *Indonesian Journal of Biotechnology*, 27(1), pp. 29–35. Available at: <https://doi.org/10.22146/ijbiotech.67506>.

- Ogino, S. and Goel, A. (2018a) 'Molecular Classification and Correlates in Colorectal Cancer', *The Journal of Molecular Diagnostics*, 10(1), pp. 13–27. Available at: <https://doi.org/10.2353/jmoldx.2008.070082>.
- Ogino, S. and Goel, A. (2018b) 'Molecular Classification and Correlates in Colorectal Cancer', *The Journal of Molecular Diagnostics*, 10(1), pp. 13–27. Available at: <https://doi.org/10.2353/jmoldx.2008.070082>.
- Ormand, A.R. *et al.* (2023) 'Mutasi Gen KRAS Ekson 2 Kodon 12 dan 13 Pada Pasien Kanker Kolorektal di RSUP Prof. Dr. I.G.N.G. Ngoerah Tahun 2018-2019', *Intisari Sains Medis*, 14(1), pp. 243–248. Available at: <https://doi.org/10.15562/ism.v14i1.1582>.
- Pascoe, M. (no date) *Kenhub Atlas of Human Anatomy*.
- Peltomäki, P. (2018) 'Update on Lynch syndrome genomics', *Familial Cancer*, 15(3), pp. 385–393. Available at: <https://doi.org/10.1007/s10689-016-9882-8>.
- Porru, M. *et al.* (2018) 'Targeting kras in metastatic colorectal cancer: Current strategies and emerging opportunities', *Journal of Experimental and Clinical Cancer Research*, 37(1), pp. 1–10. Available at: <https://doi.org/10.1186/s13046-018-0719-1>.
- Radanova, M. *et al.* (2023) 'KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer', *International Journal of Molecular Sciences*, 24(16). Available at: <https://doi.org/10.3390/ijms241612753>.
- Ranganathan, P. and Aggarwal, R. (2019) 'Study designs: Part 3 - Analytical observational studies', *Perspectives in Clinical Research*, 10(2), pp. 91–94. Available at: https://doi.org/10.4103/picr.PICR_35_19.
- Rasool, M. *et al.* (2021) 'Discovery of a novel and a rare Kristen rat sarcoma viral oncogene homolog (KRAS) gene mutation in colorectal cancer patients', *Bioengineered*, 12(1), pp. 5099–5109. Available at: <https://doi.org/10.1080/21655979.2021.1960715>.

- Ritu, K. *et al.* (2021) 'Untangling the KRAS mutated lung cancer subsets and its therapeutic implications', *Molecular Biomedicine*. Springer. Available at: <https://doi.org/10.1186/s43556-021-00061-0>.
- Rizzo, S. *et al.* (2010) 'Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?', *Cancer Treatment Reviews*, 36, pp. S56–S61. Available at: [https://doi.org/10.1016/S0305-7372\(10\)70021-9](https://doi.org/10.1016/S0305-7372(10)70021-9).
- Roszkowski, K. *et al.* (2014) 'Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome of Chemotherapy- and Radiotherapy-Treated Colorectal Adenocarcinoma Patients', *Molecular Diagnosis and Therapy*, 18(5), pp. 559–566. Available at: <https://doi.org/10.1007/s40291-014-0107-2>.
- Salimoglu, S., Kilinc, G. and Calik, B. (2020) *Anatomy of the Colon, Rectum, and Anus, Colon Polyps and Colorectal Cancer*.
- Sanz-Pamplona, R. *et al.* (2012) 'Clinical Value of Prognosis Gene Expression Signatures in Colorectal Cancer: A Systematic Review', *PLoS ONE*, 7(11), p. e48877. Available at: <https://doi.org/10.1371/journal.pone.0048877>.
- Sideris, M. and Papagrigoriadis, S. (2018) 'Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer.', *Anticancer research*, 34(5), pp. 2061–8.
- Sinicrope, F.A. *et al.* (2015) 'Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes', *Gastroenterology*, 148(1), pp. 88–99. Available at: <https://doi.org/10.1053/j.gastro.2014.09.041>.
- Soeroso, N.N. *et al.* (2021) 'The absence of mutations in the exon 2 kras gene in several ethnic groups in north sumatra may not be the main factor for lung cancer', *Acta Informatica Medica*, 29(2), pp. 108–112. Available at: <https://doi.org/10.5455/AIM.2021.29.108-112>.
- Soreide, K. *et al.* (2018) 'Advances in the understanding and treatment of colorectal cancer.', *Discovery medicine*, 12(66), pp. 393–404.

- Soumaoro, L.T. *et al.* (2018) 'Cyclooxygenase-2 Expression', *Clinical Cancer Research*, 10(24), pp. 8465–8471. Available at: <https://doi.org/10.1158/1078-0432.CCR-04-0653>.
- Styczynski, M. and Vermeersch, K. (2013) 'Applications of metabolomics in cancer research', *Journal of Carcinogenesis*, 12(1), p. 9. Available at: <https://doi.org/10.4103/1477-3163.113622>.
- Svoboda, M. *et al.* (2012) 'MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients', *Radiation Oncology*, 7(1), p. 195. Available at: <https://doi.org/10.1186/1748-717X-7-195>.
- Taieb, J. *et al.* (2023) 'Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials', *Annals of Oncology*, 34(11), pp. 1025–1034. Available at: <https://doi.org/10.1016/j.annonc.2023.08.006>.
- Tsuchida, N., Murugan, A.K. and Grieco, M. (2016) *Kirsten Ras oncogene: Significance of its discovery in human cancer research*. Available at: www.impactjournals.com/oncotarget.
- Ucar, G. *et al.* (2020) 'Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer', *Medicine (United States)*, 99(39), p. E22407. Available at: <https://doi.org/10.1097/MD.00000000000022407>.
- Wang, H. *et al.* (2023) 'Annual review of KRAS inhibitors in 2022', *European Journal of Medicinal Chemistry*, 249(5).
- Warburg, O. (1956) 'On the Origin of Cancer Cells', *Science*, 123(3191), pp. 309–314. Available at: <https://doi.org/10.1126/science.123.3191.309>.
- World Health Organization (2020) 'Cancer Incident in Indonesia', *International Agency for Research on Cancer*, 858, pp. 1–2.

- World Health Organization (2021) *Cancer colorectal, International Agency for Research Cancer*. Available at: <https://doi.org/10.1016/j.actpha.2023.01.013>.
- Yang, I.-P. *et al.* (2013a) 'The Functional Significance of MicroRNA-29c in Patients with Colorectal Cancer: A Potential Circulating Biomarker for Predicting Early Relapse', *PLoS ONE*, 8(6), p. e66842. Available at: <https://doi.org/10.1371/journal.pone.0066842>.
- Yang, I.-P. *et al.* (2018b) 'The Functional Significance of MicroRNA-29c in Patients with Colorectal Cancer: A Potential Circulating Biomarker for Predicting Early Relapse', *PLoS ONE*, 8(6), p. e66842. Available at: <https://doi.org/10.1371/journal.pone.0066842>.
- Ye, J.X. *et al.* (2015) 'KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients', *World Journal of Gastroenterology*, 21(5), pp. 1595–1605. Available at: <https://doi.org/10.3748/wjg.v21.i5.1595>.
- Yeni and Nining (2019) *Homology Modeling Epitop Mutan Protein Kirsten Rat Sarcoma (Kras) G12d, G12v Dan G12r Sebagai Kandidat Vaksin Adenokarsinoma Duktal Pankreas*. Jakarta.
- ZHANG, Y. *et al.* (2013) 'Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer', *Oncology Reports*, 30(4), pp. 1976–1984. Available at: <https://doi.org/10.3892/or.2013.2633>.
- Zhu, G. *et al.* (2021a) 'Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer', *Molecular Cancer*. BioMed Central Ltd. Available at: <https://doi.org/10.1186/s12943-021-01441-4>.
- Zhu, G. *et al.* (2021b) 'Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer', *Molecular Cancer*, 20(1), pp. 1–17. Available at: <https://doi.org/10.1186/s12943-021-01441-4>.

